GSK announces changes to the Board
GlaxoSmithKline plc announced that at the company’s Annual General Meeting (AGM) in 2013, following nine years of respective service to the GSK Board, Sir Crispin Davis, Sir Robert Wilson and Mr Larry Culp will not stand for re-election to the Board.
The Board has agreed the following succession arrangements in respect of the Committees on which they serve:
- Mr. Tom de Swaan will succeed Sir Crispin Davis as Chairman of the Remuneration Committee with effect from 1 January 2013. Mr de Swaan has been a member of the Remuneration Committee since May 2009.
- Ms. Judy Lewent will succeed Mr. Tom de Swaan as Chair of the Audit & Risk Committee with effect from 1 January 2013. Ms. Lewent has been a member of the Audit & Risk Committee since April 2011. Mr de Swaan will remain a member of the Audit & Risk Committee following Ms Lewent’s appointment.
- Sir Deryck Maughan will succeed Sir Robert Wilson as Senior Independent Non-Executive Director with effect from the closure of GSK’s AGM in 2013.
In addition, Mr. James Murdoch has decided not to stand for re-election to the Board at GSK’s AGM in 2012.ch & Development.
Most read news
Other news from the department people

Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.